p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance

[1]  Dewei Jiang,et al.  TET3‐mediated DNA oxidation promotes ATR‐dependent DNA damage response , 2017, EMBO reports.

[2]  Wenbing Xie,et al.  Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. , 2017, Molecular cell.

[3]  Thomas Efferth,et al.  The role of p53 in cancer drug resistance and targeted chemotherapy , 2016, Oncotarget.

[4]  Bram Boeckx,et al.  Tumor hypoxia causes DNA hypermethylation by reducing TET activity , 2016, Nature.

[5]  T. Horii,et al.  5-Hydroxymethylcytosine Marks Sites of DNA Damage and Promotes Genome Stability. , 2016, Cell reports.

[6]  A. Rao,et al.  Acute loss of TET function results in aggressive myeloid cancer in mice , 2015, Nature Communications.

[7]  S. Berger,et al.  Autophagy mediates degradation of nuclear lamina , 2015, Nature.

[8]  Xian Chen,et al.  CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. , 2015, Molecular cell.

[9]  A. Rao,et al.  Connections between TET proteins and aberrant DNA modification in cancer. , 2014, Trends in genetics : TIG.

[10]  Varda Rotter,et al.  The paradigm of mutant p53-expressing cancer stem cells and drug resistance. , 2014, Carcinogenesis.

[11]  L. Attardi,et al.  Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.

[12]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[13]  Yi Zhang,et al.  Regulation of TET protein stability by calpains. , 2014, Cell reports.

[14]  E. White,et al.  Autophagy-Mediated Tumor Promotion , 2013, Cell.

[15]  L. Aravind,et al.  Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX , 2013, Nature.

[16]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[17]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[18]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[19]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[21]  P. Gaulard,et al.  Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. , 2012, Blood.

[22]  E. White.  Deconvoluting the context-dependent role for autophagy in cancer , 2012, Nature Reviews Cancer.

[23]  Xiaodong Cheng,et al.  Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation , 2012, Nucleic acids research.

[24]  Yi Zhang,et al.  Replication-Dependent Loss of 5-Hydroxymethylcytosine in Mouse Preimplantation Embryos , 2011, Science.

[25]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[26]  Chuan He,et al.  Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.

[27]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[28]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[29]  Riitta Lahesmaa,et al.  Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. , 2011, Cell stem cell.

[30]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[31]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[32]  W. Bodmer,et al.  Cancer stem cells from colorectal cancer-derived cell lines , 2010, Proceedings of the National Academy of Sciences.

[33]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[34]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[35]  D. Gilliland,et al.  Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.

[36]  N. Mizushima,et al.  Autophagy: process and function. , 2007, Genes & development.

[37]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[38]  P. Johnston,et al.  Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan , 2004, Clinical Cancer Research.

[39]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[40]  B. Kaina,et al.  Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. , 2003, DNA repair.

[41]  M. Clarke,et al.  Regulation of p53 localization. , 2001, European journal of biochemistry.

[42]  K. Tsai,et al.  An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 , 2000, Nature Cell Biology.

[43]  S. Jackson,et al.  Regulation of p53 in response to DNA damage , 1999, Oncogene.

[44]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .